Pharma Mirror

APRIL 20, 2023

Copenhagen, Denmark, 20 April 2023 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific Officer (CSO) and Gabriela Burian as a new member of its Board of Directors.

Drug Development 52

Drug Development 52

Pharma Mirror

APRIL 24, 2022

Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and large-scale production of advanced biological drugs, has signed a collaboration agreement with Abera Bioscience (“Abera”) for upscaling and GMP manufacturing of its vaccine candidate against pneumococcus, Ab-01.12.

Vaccines 52

Vaccines Drug Development 52

Pharma Mirror

OCTOBER 15, 2021

Milan, InSilicoTrials has been innovating the healthcare sector for some years now, helping pharmaceutical companies reduce the time and cost of drug development using modeling & simulation. The post InSilicoTrials releases two new state-of-the-art simulation tools for oncology appeared first on Pharma Mirror Magazine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharma Mirror

NOVEMBER 23, 2021

AI is an emerging technology that is being applied in numerous facets of the pharma sector, ranging from drug development to diagnosis and even patient care. The post AI in Pharma and Biotech Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2030 appeared first on Pharma Mirror Magazine.

Drug Development 52

Drug Development 52

pharmaphorum

NOVEMBER 17, 2022

Research is based on first-hand insights gathered from within these communities, which helps inform the initial stages of clinical trial design and drug development. The post The future of clinical research in neurology must be driven by community voices appeared first on.

Drug Development 83

Drug Development 83

Pharma Mirror

FEBRUARY 11, 2021

KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. Samsung Biologics (KRX: 207940.KS) We are extremely glad to.

Immunity 52

Immunity Immunization Drug Development 52

Pharma Mirror

MAY 11, 2022

Reporting to Abzena’s chief technology officer Dr. Louise Duffy, Dr. Dieterich will use her extensive technical knowledge and leadership experience to support Abzena’s successful drug development and manufacturing operations, ultimately assisting in getting more successful treatments to patients.

Drug Development 40

Drug Development 40

Pharma Mirror

FEBRUARY 4, 2021

and China have to offer toward discovering and developing new oncology therapeutics, while using the smallest drug development program possible to do so. The post Two Immigrants, One Unique Plan For A Biopharma appeared first on Pharma Mirror Magazine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

DECEMBER 6, 2021

Access to medicines attracts a great deal of interest from patients, clinicians, and the public and there have been significant advances in drug development in recent years which looks set to continue. How the combination treatment challenge impacts patients.

Drug Development 52

Drug Development 52

pharmaphorum

NOVEMBER 24, 2021

Not only can it benefit patients by better addressing unmet needs and improving outcomes, but it makes financial sense. The post Time to take patient engagement to the next level appeared first on.

Drug Development 59

Drug Development 59

pharmaphorum

MARCH 19, 2021

As data and digital technology become vital to every aspect of life sciences, the industry is increasingly looking beyond biologists, chemists, and doctors to drive its drug development – and finding that technology has a chief role to play in the future of medicine. The post Digitalising drug discovery appeared first on.

Drug Development 59

Drug Development 59

pharmaphorum

NOVEMBER 27, 2020

New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. The interplay between technological advances, new models of drug development, and an increase in patient centricity, has created fertile ground for progress, the panel said.

Drug Development 132

Drug Development 132

pharmaphorum

OCTOBER 15, 2021

Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, putting it at the heart of commercial strategies. I don’t want to be called a patient, and I’m not on a journey.”.

Drug Development 40

Drug Development Communication 40

pharmaphorum

JULY 26, 2021

Fortunately, patients can provide valuable input across the drug development process, and the costs of accommodating this are low within the scale of investment required for R&D overall. However, despite R&D being the area of pharma most widely accepted as benefiting from the patient voice, few trials are truly patient-centric.

Drug Pricing 52

Drug Pricing Drug Development 52

pharmaphorum

OCTOBER 28, 2021

Access to medicines attracts a great deal of interest from patients, clinicians, and the public and there have been significant advances in drug development in recent years which looks set to continue. How the combination treatment challenge impacts patients and how we are working together to solve it.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

OCTOBER 1, 2021

Pharma is embracing patient centricity in drug development. Replicate a drug’s EU market success in the US requires pharma to be fully aware of the ever-changing national and state requirements and regulations, says Two Labs’ Howard Miller. Navigating the patient maze – pharma’s evolving challenge.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

JANUARY 15, 2021

It’s also important that we continue to learn and understand what patients need throughout the ecosystem, from early drug development all the way through to how patients are diagnosed and treated and their journey through these processes.”. Prior to GSK, Neale held senior commercial roles at AstraZeneca. About the author.

Vaccines 105

Vaccines Drug Development 105

pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. George Underwood is the editor for pharmaphorum’s Deep Dive digital magazine. About the author. He can be contacted on LinkedIn.

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

pharmaphorum

JANUARY 29, 2021

They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR!” From 2001 to 2012, Dr Macrae held roles of increasing responsibility at GlaxoSmithKline, including senior vice president, Emerging Markets Research and Development (R&D).

Documentation 145

Documentation Drug Development 145

pharmaphorum

MAY 18, 2021

Hale has noticed that pre-commercial companies tend to start launch planning a little too late in their drug development process. Ideally, companies should begin engaging KOLs around 24 months before the planned launch, during phase 2 of the drug’s development. About the author.

Drug Development 52

Drug Development 52

Pharma Mirror

FEBRUARY 19, 2022

NOTTINGHAM (UK) Quotient Sciences – a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and biotech industry – announces that it has integrated drug substance into its flagship Translational Pharmaceutics® platform.

Drug Development 52

Drug Development 52

pharmaphorum

DECEMBER 1, 2021

Thomas Turi, chief scientific officer at Nexelis, tells us how a biomarker-led R&D approach is transforming drug development in disease areas like non-alcoholic steatohepatitis (NASH) and cancer, and provides best-practice tips for companies looking to harness this approach.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

MAY 7, 2021

Real-world data is a vital part of rare disease drug development, but to get a true picture of patients’ unmet needs pharma should take a broader view of their lived experiences, says Xperiome’s Jeremy Edwards. He says he would like to see the industry engaging rare disease patients at every stage of drug development.

Drug Development 126

Drug Development Compounding 126

pharmaphorum

SEPTEMBER 1, 2020

George Merck on the cover of Time magazine. Thalidomide and the development of drug safety regulation and monitoring. Fordian methods enabled more rational methods of mass production, and increasing understanding of biology and chemistry enabled drug candidates to be chosen systematically rather than discovered serendipitously.

Diabetes 145

Diabetes Immunity Immunization Vaccines 145